Walleye Capital LLC Purchases Shares of 111,183 Immunome, Inc. $IMNM

Walleye Capital LLC purchased a new stake in Immunome, Inc. (NASDAQ:IMNM) during the first quarter, Holdings Channel reports. The fund purchased 111,183 shares of the company’s stock, valued at approximately $2,432,000.

Several other large investors have also recently made changes to their positions in the stock. Nan Fung Trinity HK Ltd. grew its stake in shares of Immunome by 20.7% during the fourth quarter. Nan Fung Trinity HK Ltd. now owns 714,553 shares of the company’s stock worth $15,349,000 after buying an additional 122,450 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Immunome by 1,749.3% during the fourth quarter. SG Americas Securities LLC now owns 162,168 shares of the company’s stock worth $3,483,000 after buying an additional 153,399 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Immunome by 23.4% in the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock valued at $129,705,000 after acquiring an additional 1,144,788 shares during the last quarter. Profund Advisors LLC lifted its stake in shares of Immunome by 121.7% in the 4th quarter. Profund Advisors LLC now owns 42,700 shares of the company’s stock valued at $917,000 after acquiring an additional 23,440 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Immunome during the 4th quarter valued at $3,652,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Stock Performance

Shares of NASDAQ:IMNM opened at $22.01 on Friday. Immunome, Inc. has a 52 week low of $8.66 and a 52 week high of $27.65. The firm has a market cap of $2.49 billion, a PE ratio of -9.25 and a beta of 2.07. The firm’s fifty day moving average is $21.00 and its 200-day moving average is $21.94.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. Sell-side analysts forecast that Immunome, Inc. will post -2.06 EPS for the current year.

Insider Transactions at Immunome

In other Immunome news, insider Robert Lechleider sold 55,000 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $22.62, for a total value of $1,244,100.00. Following the sale, the insider owned 15,805 shares in the company, valued at approximately $357,509.10. The trade was a 77.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 1,092 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $25.00, for a total value of $27,300.00. Following the completion of the sale, the insider directly owned 1,092 shares of the company’s stock, valued at approximately $27,300. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 472,142 shares of company stock worth $10,262,648. 7.21% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

IMNM has been the topic of a number of research reports. Wedbush restated an “outperform” rating and set a $31.00 price objective on shares of Immunome in a research report on Tuesday. Wall Street Zen downgraded Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research note on Friday, July 17th. Citigroup restated a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Finally, Barclays assumed coverage on Immunome in a research note on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price objective for the company. Thirteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Immunome presently has an average rating of “Moderate Buy” and an average target price of $33.17.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.